NCT05003986Phase 2Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Study sponsor: Travere Therapeutics, Inc. · TVTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-03-12Estimated

Enrollment · participants67Estimated

Source updated2026-05-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy; IgA Vasculitis; Alport Syndrome

Treatments or interventions studied

SparsentanDrugAlso known as RE-021
SparsentanDrugAlso known as RE-021
SparsentanDrugAlso known as RE-021

Primary outcomes · main study measures

Read the study measures

measure: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of interest (AEOIs); description: The incidence of TEAEs, SAEs, AEs leading to treatment discontinuation, and AEOIs; timeFrame: After the last patient has undergone the week 108 visit (Visit 15).; measure: Urine protein/creatinine ratio (UP/C) at week 108; description: Change from baseline in UP/C over 108 weeks; timeFrame: After the last patient has undergone the Week 108 visit (Visit 15)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history